This is a paid press release. Contact the press release distributor directly with any enquiries.
BioSyent Releases Financial Results for Q2 and H1 2026
MISSISSAUGA, Ontario, Aug. 20, 2026 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its consolidated financial results for the three months (Q2), six months (H1), and trailing twelve months (TTM) ended June 30, 2026. Key highlights include:
-
Q2 2026 was first full quarter of financial results contributed by Oral Health segment following March 1, 2026 acquisition of Oral Science Inc.:
-
$1.1 million NIAT (before $0.75 million amortization expense on acquired intangible assets)
-
-
Q2 2026 consolidated EBITDA1 margin: 25% to sales (26% to sales – adjusted for one-time acquisition costs)
-
H1 2026 consolidated EBITDA1 margin: 26% to sales (27% to sales – adjusted for one-time acquisition costs)
-
Return on Average Equity for the trailing twelve months (‘TTM’) ended June 30, 2026 was 24%, increasing from 23% for TTM June 30, 2025
-
During H1 2026, repurchased and cancelled a total of 218,500 common shares under a Normal Course Issuer Bid (NCIB)
-
Paid quarterly cash dividends of $0.055 per common share on March 13, 2026 and June 15, 2026
-
Declared subsequent cash dividend of $0.055 per common share to be paid on September 15, 2026
“We are very pleased with the first full quarter of operating results delivered by our new Oral Health segment in Q2 2026,” commented Mr. René Goehrum, President and CEO of BioSyent. “The added sales and profit from the Oral Health segment when combined with continued growth in our existing Pharmaceutical segment, both in Canada and internationally, resulted in total Company quarterly sales and EBITDA1 growth of 95% and 80%, respectively, over the comparative quarter. With H1 2026 operating cash flows from the Oral Health segment of $1.3 million since the March 1st acquisition date combined with $3.9 million in H1 2026 operating cash flows from our Pharmaceutical and Insecticide businesses, we continued to invest in growing all of our businesses in H1 2026 in addition to paying down our short term acquisition debt, buying back shares under our Normal Course Issuer Bid, and paying regular quarterly dividends. Though we continue to face economic uncertainty in Canada and geopolitical instability internationally, we are well-positioned with a strong balance sheet and more diversified product portfolio, to continue to deliver on our strategic priorities of profitable growth, portfolio diversification and long-term value creation for our shareholders.”
